





4TH INTERNATIONAL HIV/VIRAL HEPATITIS CO-INFECTION MEETING

**THE ROCKY ROAD TO VIRAL HEPATITIS ELIMINATION:
ASSURING ACCESS TO ANTIVIRAL THERAPY FOR ALL
CO-INFECTED PATIENTS FROM LOW TO HIGH INCOME SETTINGS**

22 - 23 JULY 2017

Amphithéâtre Farabeuf, Campus des Cordeliers, Université Pierre et Marie Curie (UPMC)

21 rue de l'Ecole de Médecine, Paris, France



PARTNERS

DONORS



EACS European
AIDS Clinical Society



National Institute
on Drug Abuse

SPONSORS



Abbott

abbvie



HETERO



WITH SUPPORT FROM



the **CTN**
CIHR Canadian
HIV Trials Network

le **Réseau**
Réseau canadien
pour les essais VIH des IRSC



MEETING OVERVIEW

The 4th International HIV/Viral Hepatitis Co-Infection Meeting is organized by the International AIDS Society (IAS) and takes place prior to the 9th IAS Conference on HIV Science (IAS 2017) at the Campus des Cordeliers, Université Pierre et Marie Curie (UPMC) in Paris, France.

Building on the previous three successful annual meetings, the 4th International HIV/Viral Hepatitis Co-Infection Meeting provides a unique opportunity to bring together a diversity of scientific, technical and community interests to discuss current opportunities and challenges for increased prevention, diagnosis and treatment of viral hepatitis in people living with HIV. While the focus of the 3rd International HIV/Viral Hepatitis Co-Infection Meeting was on medical and access challenges in low- and middle-income settings in particular, the 4th meeting also takes advantage of the meeting location to explore the reality faced by people co-infected with HIV and viral hepatitis in high-income countries and across Eastern Europe and Central Asia. It is also an opportunity to take stock of some of the scientific breakthroughs and brainstorm on concrete actions to support the WHO targets in their sector strategies.



The meeting focuses on addressing the challenges of achieving elimination of hepatitis B and C in HIV-infected populations worldwide through reviewing the latest information on epidemiology, prevention, diagnostics and treatment. Furthermore, the meeting has a particular focus on access to care and new curative treatments especially for vulnerable populations with overlapping risk for both HIV and viral hepatitis, such as people who inject drugs, prisoners and men who have sex with men. These topics are explored through a combination of keynote presentations to provide broad and assertive overviews of the different areas, invited and abstract-based oral and poster presentations to highlight cutting-edge science, and invited panel discussions and debates, with strong community participation, to go beyond the data and address the obstacles that continue to hinder the full implementation of available diagnostic and treatment options.

PROGRAMME

SATURDAY 22 JULY

08:00 – 08:30 Registration and welcome coffee

Welcome and introduction

08:30 – 08:40 Meeting opening Marina Klein

08:40 – 09:00 Welcome to France: Update on the role of community research for hepatitis prevention Patrizia Carrieri

Taking stock | Session co-chairs: Linda-Gail Bekker and Oluwaseun Falade-Nwulia

09:00 – 09:25 Update on global epidemiology/elimination targets: Are we on track? Gottfried Hirnschall

09:25 – 10:15 Emerging epidemics: Will they derail progress?
• Eastern/Central Europe Marieta Simonova
• Rural HIV-HCV related epidemics in the USA John T. Brooks

10:15 – 10:40 Where are we now on priorities identified at Durban? Monique Andersson

10:40 – 10:50 Discussion All speakers

10:50 – 11:15 Break & poster viewing

Diagnostics | Session co-chairs: Anne Loarec and Amare Eshetu

11:15 – 11:35 New diagnostics: Point of care testing for HCV Jordan Feld

11:35 – 11:55 The evolution in HBV markers Slim Fourati

11:55 – 12:15 Approaches for simplified diagnostic/screening algorithms Niklas Luhmann

12:15 – 12:30 Discussion All speakers

12:30 – 13:45 Lunch & poster viewing

12:30 - 13:10 – Epidemiology
HBV

13:10 - 13:45 – Immunology
Diagnostics
Linkage to care

Linkage to care: Different strokes for different folks?

Session co-chairs: Sergii Dvoriak and Nadine Kronfli

13:45 – 14:00	People who inject drugs	Margaret Hellard
14:00 – 14:15	Prisoners	Rick Altice
14:15 – 14:30	Men who have sex with men	Andri Rauch
14:30 – 14:45	Community-driven programmes	Anton Basenko
14:45 – 15:00	Discussion	All speakers
15:00 - 15:15	Break & poster viewing	

Treatment | Session co-chairs: Mauro Schechter and Christoph Boesecke

15:15 – 15:40	Treatment guidelines update	Alessio Aghemo
15:40 – 16:05	Shorter durations and pan-genotypic regimens: The final frontier?	Greg Dore
16:05 – 16:30	HCV treatment in active PWID: Is there a concern about reinfection?	Jason Grebely
16:30 – 16:55	What do clinicians need to watch for with DAA therapy?	Jürgen Rockstroh
16:55 – 17:25	Case discussions (difficult management issues in HCV/HBV) <ul style="list-style-type: none">• Case discussion 1• Case discussion 2	Sanjay Bhagani Lionel Piroth
17:25 – 17:30	Discussion	All speakers
17:30 – 20:00	Reception & poster viewing 17:30 - 18:10 – Treatment Scale-up 18:10 - 18:50 – Outcomes and co-morbidities	

SUNDAY 23 JULY

08:00 – 08:30 Welcome coffee

Bringing it together: The scale up | Session co-chairs: Kenneth Ngure and Linda Wittkop

08:30 – 08:50 Is elimination possible and what will it take to achieve it? Natasha Martin

08:50 – 09:10 Test and treat: Dutch MSM treatment experience Bart J.A. Rijnders

09:10 – 09:30 Economics and sustainability: The role of generics Andrew Hill

09:30 – 09:50 Access in high income countries: The European landscape Jeffrey Lazarus

09:50 – 10:10 Community experience with expanded access Pascal Mélin

10:10 – 10:15 Discussion All speakers

Looking to the future | Session co-chairs: Adeeba Kamarulzaman and Jacques Normand

10:15 – 10:35 Research gaps in viral hepatitis Jean-Michel Pawlotsky

10:35 – 10:55 HAV outbreak in Europe Anne-Marie Rique-Afonso

10:55 – 11:00 Discussion All Speakers

11:00 – 11:15 Break & poster viewing

Panel discussion: Priorities for enhancing access and how to achieve them | Session chair: Tracy Swan

11:15 – 11:30 Global state of HCV treatment access Tracy Swan

11:30 – 12:30 Panel discussion (Roundtable and audience participation) Isabelle Andrieux-Meyer, Anton Basenko, James Freeman, Céline Grillon, Othoman Mellouk, Luís Mendão

Closing

12:30 – 12:45 Meeting summary Karine Lacombe

12:45 – 13:00 Moving forward to address HIV co-infections and co-morbidities Anton Pozniak

POSTER ABSTRACTS

EPIDEMIOLOGY

1. Assessment of prevalence of HIV, hepatitis C, HIV/hepatitis C co-infection and risk behaviours among female injecting drug users in Nepal

J. Damas, K. Deuba, U. Shrestha, B. Rawal, T. Paudel, G. Marrone

2. Burden of infectious diseases and substance abuse among incarcerated women in Kuala Lumpur, Malaysia

V. Pillai, C. Pedersen, J. Wickersham, F. Altice, A. Kamarulzaman

3. Chronic hepatitis C and HIV co-infection among people who inject drugs along the Kenyan Coast

R.N. Shah, J. Kinyua, A. Kattammaiyo, K. Mandaliya, B. Langat, S. Bhagani, M. Thursz, E. Songok, M. Lemoine

4. Countrywide epidemiology of B, C and Delta hepatitis in Burkina Faso: The ANRS 12270 clustered cross-sectional study

N. Meda, E. Tuillon, D. Kania, A. Kiendrebeogo, A. Pisoni, S. Zida, K. Bollore, I. Meda, D. Laureillard, J.P. Moles, N. Nagot, Y. Nebie, P. Vande Perre, P.F. Dujols

5. Crystal methamphetamine initiation among HIV-positive and HIV-negative men who have sex with men in Vancouver, Canada: A longitudinal analysis

N.J. Lachowsky, M. Hull, Z. Cui, J. Zhu, H. Armstrong, M. Taylor, J. Edwards, G. Olarewaju, R. Hogg, E.A. Roth, D.M. Moore, Momentum Health Study

6. HCV genotype profile in Brazil among HIV infected and uninfected individuals: A survey truly representative of an entire country

M. Nutini, J. Hunter, A.F. Pires, I. Kohiyama, M. Camargo, M.C. Sucupira, D. Ricardo

7. Hepatitis E virus serological and molecular testing in 1979 patients followed-up in 2014-2016 in HIV reference centers of university hospitals of Marseille, southeastern France

P. Colson, C. Dhiver, H. Tissot-Dupont, S. Mokhtari, A. Motte, I. Ravaux, C. Toméi, C. Tamalet, S. Aherfi, P. Brouqui, A. Stein, A. Menard

8. Predictors and incidence of sexually transmitted hepatitis C virus infection in HIV positive men who have sex with men

N.A. Medland, C. Eric P F, C.S. Bradshaw, T.H.R. Read, J.J. Sasadeuz, C.K. Fairley

9. Predictors of HCV seroconversion in people who inject drugs in 5 regions of Ukraine

A. Meteliuk, A. Mazhnaya, S. Filipovych, F.L. Altice

10. Prevalence and risk factors associated with HIV/viral hepatitis B and C co-infections among people who inject drugs in Mozambique, 2013-2014

C.A. Semá Baltazar, M. Boothe, I. Sathane, E. Fazito, R. Horth, N. Bhatt

11. Recent incarceration and risk of hepatitis C and HIV transmission amongst people who inject drugs: A systematic review and meta-analysis

J. Stone, M. Hickman, A. Lim, H. Fraser, J. Walker, L. MacGregor, A. Trickey, S. Abbott, Z. Ward, N.K. Martin, P. Vickerman

12. Trends in cause-specific mortality in HIV-hepatitis C (HCV) co-infected patients in Canada (2003 - 2016): Early impact of HCV therapy

N. Kronfli, S.R. Bhatnagar, M. Hull, E. Moodie, C. Cooper, N. Pick, S. Walmsley, M.-L. Vachon, V. Martel-Lefrierre, J. Gill, M. Klein, on behalf of the Canadian Co-Infection Cohort Investigators

13. Circulating mucosal associated invariant T cells (MAITs) fail to be recovered by successful direct-acting antiviral therapy (DAA) in HIV/HCV co-infected patients

E.S. Cannizzo, M. Cerrone, E. Merlini, B. van Wilgenburg, L. Swadling, C. Tincati, A. De Bona, A. d'Arminio Monforte, P. Klenerman, G. Marchetti

14. Untreated HCV-coinfection in HIV-infected patients induces additional CD4+ T-lymphocyte deficiency due to mobilization of naive cells into immune response resulting in their regeneration failure

K. Shmagel, E. Saidakova, L. Korolevskaya, N. Shmagel, V. Chereshnev

DIAGNOSTICS

15. Chronic hepatitis C among intravenous drug users in Tanzania: Assessment of the liver disease and utility of HCV core antigen detection and quantification

Z. Mohamed, J. Mbwambo, Y. Shimakawa, L. Poiteau, S. Chevaliez, J.-M. Pawlotsky, J. Rwegasha, S. Bhagani, S. Taylor-Robinson, J. Makani, M. Thursz, M. Lemoine

16. Comparison of two immunoassays for simultaneous detection of HCV antigen and antibodies among HCV/HIV co-infected patients in dried serum spots

A. Eshetu, B. Bartmeyer, V. Bremer, D. Schmidt, C.-T. Bock, N. Bannert, A. Hauser

17. Usual APRI score thresholds lack sensitivity to prioritize for hepatitis C treatment in a HCV/HIV coinfecting cohort in Cambodia

A. De Weggheleire, S. An, J. Buyze, S. Thai, S. Franque, L. Lynen

18. Validation and scale-up of hepatitis B viral load on polyvalent open PCR platforms in West African and South East Asian countries. A study of the AC12 working group (ANRS 12327)

D. Kanja, F. Rouet, K. Bolloré, J. Nouhin, R. Njouom, T.D. Toni, A. Maiga, C. Touré-Kane, N. Ngo-Giang-Huong, A. Dagnra, D.H.C. Le, F. Lunel-Fabiani, M.-L. Chaix, J. Castéra-Guy, J.-M. Da Costa Castro, C. Rouzioux, J.-C. Plantier, E. Tuillon

LINKAGE TO CARE

19. Hepatitis C care cascade for people living with HIV in the country of Georgia

N. Chkhartishvili, A. Abutidze, N. Bolokadze, O. Chokoshvili, N. Dvali, L. Sharvadze, T. Tsertsvadze

20. Integrated Surveillance for HIV, syphilis, HBV & HCV in pregnant women attending ANC sentinel surveillance sites in Eritrea, 2016

A.B. Mesfin, H. Ahmed, M. Asrat, T. Asfaha, N. Tesfamichael

TREATMENT

21. Alanine aminotransferase level monitoring to detect hepatitis B virus reactivation in 170 HIV/hepatitis C virus-infected patients on direct-acting agent-based therapies

P. Colson, S. Mokhtari, H. Tissot-Dupont, C. Diver, I. Ravaux, L. Meddeb, A. Motte, C. Tamalet, S. Aherfi, P. Brouqui, A. Stein, A. Menard

22. Association of uncontrolled HIV-RNA with failure to direct acting antiviral (DAA) combinations in HIV/HCV co-infected patients on antiretroviral therapy (ART) - ANRS CO13 HEPAVIH cohort

D. Salmon, C. Gilbert, J. Chas, L. Piroth, K. Lacombe, C. Katlama, P. Trimoulet, C. Solas, G. Peytavin, H. Aumaitre, L. Alric, F. Boué, P. Morlat, I. Poizot-Martin, E. Billaud, E. Rosenthal, A. Naqvi, P. Mialhes, L. Esterle, P. Carrieri, P. Sogni, F. Dabis, L. Wittkop, HEPAVIH ANRS CO13 Study Group

23. Chronic hepatitis C in human immunodeficiency virus infected patients: Real-life treatment with new generation direct-acting antivirals in a Portuguese centre

A. Silva-Pinto, R. Ruas, I. Abreu, F. Ceia, A.C. Carvalho, N. Neves, A.S. Santos, J. Soares, C. Piñeiro, R. Serrão, A. Sarmento

24. Efficacy and safety of Glecaprevir/Pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: The EXPEDITION-2 study

J. Rockstroh, K. Lacombe, R. Viani, C. Orkin, D. Wyles, A. Luetkemeyer, R. Soto-Malave, R. Flisiak, S. Bhagani, K. Sherman, P. Ruane, J. Sasadeusz, J. Slim, Z. Zhang, T. Ng, R. Trinh, M. Sulkowski

25. Evolution of glomerular filtration rate in patients concomitantly treated with ledipasvir and tenofovir

M. Fabbiani, I. De Benedetto, G. Lapadula, R. Gagliardini, A. Soria, D. Moschese, A. Muscatello, M. Rossi, N. Squillace, A. Bandera, A. De Luca, S. Di Giambenedetto, A. Gori

26. HCV cure for HIV-infected patients: Not so easy to achieve in routine practice

H. Laroche, C. Lions, C. Solas, P. Carrieri, O. Faucher-Zaegel, S. Bregigeon, C. Tamalet, E. Ressiot, V. Obry-Roguet, B. Canet, I. Poizot-Martin

27. Role of PLHIV networks in facilitating hepatitis C cascade of care in South and South East Asia

O. Syarif

28. The road to elimination of hepatitis C: Analysis of SVR versus new HCV infections in 91 countries

A. Hill, S. Nath, B. Simmons

29. The Global Accelerator for Paediatric Formulations (GAP-f): Ensuring children have accelerated access to optimal drug formulations

S. Morin, M. Vicari, M. Watkins, L. Lewis, F. Pascual, P. Easterbrook, M. Penazzato, GAP-f partners

30. Causes of death in HIV-monoinfected and HIV/HCV-coinfected patients in Brazil, 2000-2014

M.E. Santos, R. Abrahão Ribeiro, A. Stevens, M.P. Carrieri, W. Navegantes de Araújo

31. Coffee intake modifies the relationship between alcohol consumption and liver fibrosis in patients co-infected with HIV and hepatitis C virus (ANRS CO13-HEPAVIH cohort)

M.E. Santos, S. Rosellini, F. Marcellin, C. Protopopescu, L. Wittkop, L. Esterle, P. Morlat, D. Zucman, A. Gervais, B. Spire, F. Dabis, D. Salmon-Ceron, M.P. Carrieri, ANRS CO13-HEPAVIH Cohort Study Group

32. Comparative steatosis rates by liver biopsy and transient elastography controlled attenuated parameter (CAP) in hepatitis C (HCV) and HIV/HCV coinfection in a large U.S. hepatitis clinic: Time to take notice

J. Martin, O. Adeyemi, K. Burke, I. Alvaraz, C. Winston, S. Markham, B. Go, G. Huhn

33. Daily cannabis use and reduced risk of severe steatosis in a population of patients co-infected with HIV and hepatitis C virus (HCV) (ANRS CO13-HEPAVIH)

S.E. Nordmann, A. Vilotitch, P. Roux, L. Esterle, B. Spire, F. Marcellin, D. Salmon-Ceron, F. Dabis, J. Chas, D. Rey, L. Wittkop, P. Sogni, P. Carrieri, ANRS CO13 HEPAVIH study group

34. Does the non-alcoholic fatty liver disease (NAFLD) score predict liver fibrosis progression after hepatitis C virus (HCV) treatment in human immunodeficiency virus (HIV)-HCV co-infected patients?

N. Kronfli, R. Nitulescu, S. Walmsley, C. Cooper, S. Haider, J. Gill, M.-L. Vachon, M. Klein, on behalf of the Canadian Co-Infection Cohort Investigators

35. Effects of long-term ART on total HIV DNA levels in Japanese patients with and without haemophilia+HCV

K.R. Stanoeva, A. König, A. Fukuda, Y. Kawanami, T. Kuwata, Y. Satou, [S. Matsushita](#)

36. Increased risk of overweightness and obesity after HCV clearance in patients co-infected with HIV and hepatitis C virus (HCV) (ANRS CO13-HEPAVIH cohort)

I. Yaya, C. Protopopescu, F. Marcellin, L. Wittkop, L. Esterle, D. Salmon-Céron, I. Poizat-Martin, E. Rosenthal, F. Bani-Sadr, S. Nordmann, M.P. Carrieri, The ANRS CO13-HEPAVIH Study Group

37. Occult liver cirrhosis diagnosed by transient elastography is frequent and under-monitored in HIV-infected patients: Results of a large-scale screening program

A. Benmassaoud, T. Pembroke, B. Lebouche, P. Ghali, M. Deschenes, M. Klein, G. Sebastiani

38. Sustained virologic response (SVR) after hepatitis C virus (HCV) treatment does not lead to improved renal function in HIV/HCV coinfecting patients

C. Rossi, E. Moodie, M. Hull, V. Martel-Lafferriere, M.-L. Vachon, C. Cooper, N. Pick, S. Walmsley, [M. Klein](#), Canadian Coinfection Cohort

SCALE-UP

39. An economic evaluation of the integrated approach for triple elimination of mother-to-child transmission of HIV, hepatitis B and syphilis

L. Zhang, [L. Ferradini](#), N. Ishikawa, J.V. Woodring, Y. Tao, M. Nagai, Y.-R. Lo

40. Eliminating HCV/HIV coinfection through enhanced treatment: HCV treatment in primary care is feasible and highly effective

[A.L. Bowring](#), J.S. Doyle, J. Roney, D. Iser, J. Sasadeusz, M. O'Reilly, C. Fairley, E. Gane, H. Jennifer, G.V. Matthews, N. Medland, R. Moore, M. Prins, M. Stoové, B.-K. Tee, M. Hellard E

41. Expanding the provider base: HIV and hepatitis C clinical preceptorships in New York State

N. Harris, [T. Wilder](#), J. Steinke, R. Walsh, A. Urbina

42. Generic treatments for HIV, HBV, HCV, TB could be mass produced for < \$90 per patient

A. Hill, M. Barber, [D. Gotham](#), J. Fortunak, A. Pozniak

43. Georgia's path towards HCV elimination

L. Sulaberidze, I. Chikovani, M. Uchaneishvili, [N. Shengelia](#)

HBV

44. HBV co-infection is associated with high one-year mortality in HIV-infected Tanzanians on ART

Christian, E. Fabian, L.R. Ammerman, I. Macha, C. Gawile, S. Mpangala, N. Ulena, C. Thio, R. Murphy, [C. Hawkins](#)

45. Hepatitis B virus infection in HIV-1 negative and positive pregnant women in Botswana, implications for HBV vertical transmission

[T. Mbangiwa](#), M. Anderson, A. Needleman, P.K. Thami, M. Leteane, S. Moyo, D. Setlhare, G. Mayondi, T. Sebunya, T.W. Choga, R. Musonda, M. Essex, S. Lockman, S. Gaseitsiwe

46. Preliminary results of prevention of mother-to-child transmission of hepatitis B virus through treatment of mothers and vaccination of newborns at Ouagadougou, Burkina Faso

[A.N. Guingane](#), N. Meda, R. Sombié, I. Guiraud, A. Bougouma

4TH INTERNATIONAL HIV/VIRAL HEPATITIS CO-INFECTION MEETING

**THE ROCKY ROAD TO VIRAL HEPATITIS ELIMINATION: ASSURING
ACCESS TO ANTIVIRAL THERAPY FOR ALL CO-INFECTED PATIENTS
FROM LOW TO HIGH INCOME SETTINGS**

CO-CHAIRS

MARINA KLEIN

McGill University
CIHR Canadian HIV Trials Network
Montreal, Canada

KARINE LACOMBE

Hôpital Saint-Antoine
Paris, France

ORGANIZING COMMITTEE MEMBERS

MONIQUE ANDERSSON

Stellenbosch University, Faculty of Health Science
Cape Town, South Africa

GAIL MATTHEWS

Kirby Institute
Sydney, Australia

ISABELLE ANDRIEUX-MEYER

Drugs for Neglected Diseases initiative
Geneva, Switzerland

SÉBASTIEN MORIN

International AIDS Society
Geneva, Switzerland

SANJAY BHAGANI

Royal Free Hospital
London, UK

JACQUES NORMAND

National Institute on Drug Abuse
Washington D.C., USA

CHRISTOPH BOESECKE

University of Bonn
Bonn, Germany

JEAN-MICHEL PAWLOTSKY

Henri Mondor University Hospital
Créteil, France

LAURENT CASTERA

Hôpital Beaujon
Paris, France

MARION PETERS

University of California
San Francisco, USA

GREG DORE

Kirby Institute
Sydney, Australia

LIONEL PIROTH

CHU Dijon Bourgogne
Dijon, France

JORDAN FELD

University of Toronto
Toronto, Canada

JÜRGEN ROCKSTROH

University of Bonn
Bonn, Germany

NIKLAS LUHMANN


Médecins du Monde
Paris, France

TRACY SWAN

Freelancer
New York, USA

LUDMILA MAISTAT

Alliance for Public Health
Kiev, Ukraine



www.iasociety.org

